LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Healthy Planet, Healthy People: a Pathway for Green Transition in the Biopharmaceutical Ecosystem

26/10/2021
NEWS RELEASE
Healthy Planet, Healthy People: a Pathway for Green Transition in the Biopharmaceutical Ecosystem

Brussels, 26 October 2021- On the 25th of October, as part of its 25th Anniversary programme, EuropaBio and member Novartis invited the healthcare community and relevant stakeholders to focus on the green transition and how it will shape healthcare for us all.

Event speakers were:

• Carmen Laplaza, Head of Unit, Health Innovations and Ecosystems, DG Research and Innovation
• Montserrat Montaner, Chief Sustainability Officer, Novartis
• Jutta Paulus, Member of the European Parliament, Group of the Greens, Germany
• Dr. Wouter De Soete, Manager Centre of Excellence in Sustainable Pharmaceutical Engineering & Manufacturing, University of Ghent
• Kristin Schreiber, Director, Directorate Ecosystems: Chemicals, Food, Retail, Health, DG Grow, European Commission

Dr. Claire Skentelbery, Director General, EuropaBio moderated the discussion.

The event was kicked off with opening comments from Jutta Paulus, MEP, Group of the Greens. Mrs Paulus stressed the importance of better preparedness for the next pandemics and, at the same time, lowering our impact on biodiversity and the environment. According to MEP Paulus, only when we find a more sustainable way to manage wastewater and animals and produce materials, including biopharmaceuticals, can we protect ourselves from further environmental damage.

Montse Montaner, Chief Sustainability Officer of Novartis continued the discussion, with some key Novartis priorities regarding sustainability of biopharmaceuticals. She stated that Novartis has a goal to minimise impact on the planet, reach carbon neutrality across the value chain by 2030 and become net zero by 2040. Novartis also aims to be water sustainable and plastic neutral by 2030.

Carmen Laplaza, Head of Unit, Health Innovations and Ecosystems, DG Research and Innovation, pointed out that the tendency of pharmaceutical manufacturing leaving the European Union, creates vulnerabilities in the supply chain which needs to be addressed, not only from the environmental point perspective but also taking into account economic and health related issues. She stated that various EC instruments in the context of Horizon Europe such as collaborative grants, partnerships and missions are addressing these ongoing challenges.

Wouter De Soete, Manager of the Centre of Excellence in Sustainable Pharmaceutical Engineering & Manufacturing, University of Ghent, highlighted that integrating sustainability aspects early in the biomanufacturing process helps to position sustainability not as a burden but rather as an opportunity for business and innovation. He also stressed the importance of the knowledge triangle, a key ingredient to creating local ecosystems that can attract investments.

Kristin Schreiber, Director, Directorate Ecosystems: Chemicals, Food, Retail, Health, DG Grow stated that the European Commission is looking at the co-creation process together with industry, public authorities and social partners to establish green and digital pathways for the different ecosystems. She added that the sustainability aspect must be very much in the forefront and include a much better understanding of the cost long-term benefits.

The event recording is available here.

Healthy Planet, Healthy People


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

EuropaBio AGM 2025: Association Chair, Executive Committee and Board announced


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.